drugset / Trial / NCT06590259
A Study on the Efficacy and Safety of Multi-mode Ablation Combined With Systemic Therapy in the Treatment of CRCLM
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate the efficacy and safety of multi-mode ablation combined with systemic therapy including PD-1(programmed death receptor 1) inhibitor for colorectal cancer liver metastasis and furthermore to clarify its application value by comparing preoperative and postoperative immune indicators.
Timeline
- Start
- 2024-03-12
- Primary completion
- 2027-07
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |